Stefanie Dimmeler appointed as Chief Editor of EMBO Molecular Medicine
Heidelberg, Germany, 1 February 2011 – The European Molecular Biology Organization (EMBO) announces the appointment of Professor Stefanie Dimmeler as Chief Editor of the scientific journal EMBO Molecular Medicine.* Dr. Dimmeler is Professor of Experimental Medicine and Director of the Institute of Cardiovascular Regeneration, Center for Molecular Medicine at the Goethe University Frankfurt.
"We are pleased to welcome Stefanie Dimmeler as chief editor of EMBO Molecular Medicine," said Maria Leptin, EMBO Director. "Stefanieʼs recognized contributions to molecular cardiology and experimental medicine will serve her well in this lead role on the EMBO editorial team."
Since the first issue in April 2009, EMBO Molecular Medicine is recognized for its global reach and broad scope that result in the publication of high-quality research at the interface of molecular biology and clinical research.
"As a researcher who is dedicated to translational medicine, I am delighted to join the editorial team for EMBO Molecular Medicine," said Stefanie Dimmeler in response to her appointment as chief editor, a role she took on in January 2011. "Scientists need a journal to bridge the worlds of basic and clinical science. To link the strong EMBO reputation in the molecular world with the world of patient studies by reporting novel and exciting therapeutic approaches across disciplines is an effective way to successfully build that bridge."
In her position as chief editor, Stefanie aims to increase the visibility of the journal across all medical disciplines. She dreams that the journal will one day become the ʻbasic science-orientedʼ equivalent to the New England Journal of Medicine, with a similar impact. "This will be along way to go – but worth the effort!" she said. Professor Dimmelerʼs research focuses on endothelial cell biology, including signal transduction, apoptotic mechanisms and vascular renewal by circulating endothelial progenitor cells. She has identified novel signalling pathways mediating the synthesis and release of the endothelial protective factor NO (nitric oxide). The scientific discoveries achieved from joint research conducted by Professor Dimmeler and Dr. Andreas M. Zeiher, Professor and Director of the Department of Cardiology, Angiology/Haematology, Nephrology at the Goethe University Frankfurt, have resulted in current clinical trials of human progenitor cells for cardiovascular repair. Her group is presently working on microRNA- based therapeutics for cardiovascular diseases.
After her PhD from the University of Konstanz in Germany, Stefanie Dimmeler completed a fellowship in Experimental Surgery at the University of Cologne and in Molecular Cardiology at the Goethe University Frankfurt. She became Professor of Experimental Medicine at the Institute of Cardiovascular Regeneration, Center for Molecular Medicine, Goethe University Frankfurt in 2001. In 2008, she took on the role of director for the institute.
She is author of more than 200 papers published in highly cited journals and has been invited to speak at more than 250 conferences and seminars. Her research achievements have been widely recognized with prestigious awards that include the Award of the German Heart Foundation in 1998, the Frankel-Preis of the German Cardiac Society in 2000, the Alfried Krupp Award 2002, the Leibniz Award 2005, the Award of the Jung Foundation 2007 and the FEBS award 2006. She presented the George E. Brown Memorial Lecture at the Scientific Sessions of the American Heart Association Congress in 2005 and the Basic Science Lecture of the European Society of Cardiology in 2006. She has recently received the GSK research award 2010 for her work on microRNAs.
Professor Dimmeler serves on the editorial boards of a number of journals: The Journal of Clinical Investigation, Circulation, Circulation Research, Basic Research in Cardiology. She is associate editor of Circulation Research and European Heart Journal. She is co- director of the Transatlantic Network of Cardiac Regeneration supported by the Leducq Foundation and member of the Steering Committee of the ʻExcellence Cluster Cardio- Pulmonary Systemʼ (ECCPS), a translational research center in the field of vascular and parenchymal heart and lung diseases, funded by the DFG (Deutsche Forschungsgemeinschaft) in Germany.
* EMBO Molecular Medicine is published on behalf of EMBO by Wiley-Blackwell.
T. + 49 6221 8891 111